In conclusion, a risk model constructed by 6 hypoxia-driven genes (WT1, HOXA2, HOXC6, MMP9, SHOX2 and MYOD1) provide valuable clinical utility for the prognostic prediction of glioma patients. This evidence concerns the gene HOXA2 and central nervous system cancer.